Content for healthcare professionals only

View all Platforms Cardiology

Topics Content Type Videos Articles Journals Broadcasts Education Podcasts News Journals AER CFR ECR ICR3 JAPSC USC Faculty Events Upcoming Events Radcliffe Events All Events Resource Hubs Empagliflozin in the Treatment of Chronic Heart Failure Pulmonary Embolism Pulsed Field Ablation

Radcliffe Platforms

Radcliffe Group Cardiology Vascular CVRM Medical Education

Content for healthcare professionals only

Content Type

Events

Resource Hubs

Optimising RAASi Management in Cardiorenal Patients: An Expert Roundtable

Published: 23 April 2024

Views:
8921
Likes:
7

Views:
8921
Likes:
7
Share:

Now Playing
Part 1 | Session 2 of 3
Case Presentation
Aaron Wong

Up Next
14m 31s

Part 1 | Session 3 Panel Discussion and Q&A
Andrew Frankel, Shelley Zieroth, Aaron Wong, Manish Sood

12m 18s

Part 2 | Session 1 Barriers and Real-world Evidence
Manish Sood
9m 20s

Part 2 | Session 2 Panel Discussion and Q&A
Andrew Frankel, Shelley Zieroth, Manish Sood , Aaron Wong

1m 15s

Part 3 Key Learnings / Summary
Andrew Frankel

15m 4s

Part 1 | Session 1 Background and Guidelines Andrew Frankel, Shelley Zieroth, Aaron Wong, Manish Sood

Average (ratings)

No ratings

Your rating

Overview

In this on-demand version of the live roundtable, cardiologists Dr Shelley Zieroth (University of Manitoba, Winnipeg, CA) and Dr Aaron Wong (Princess of Wales Hospital, Wales, UK) join nephrologists Dr Andrew Frankel (Imperial College Healthcare NHS Trust, London, UK), and Dr Manish Sood (University of Ottawa, CA) to discuss the nuanced landscape of RAASi management in cardiorenal patients.

In this discussion, our expert faculty consider approaches to optimal RAASi dosing and strategies to improve patient outcomes. The programme integrates data-driven insights, established guidelines, and expert consensus, offering participants a holistic understanding of RAASi management.

A case study highlights how to overcome barriers to optimal guideline-directed medical therapy and panel discussion will bridge theory and real-world application, providing you with actionable tools to implement optimal practices in your daily clinical pursuits.

This programme is supported by an unrestricted educational grant from AstraZeneca.

Learning Objectives

Describe the prevalence and clinical impact of sub-optimal RAASi use in cardiorenal patients
Recall key messages from current guidelines, consensus and clinical evidence for optimised RAASi management in cardiorenal patients
Describe common barriers to optimise RAASi management strategies
Use expert-led guidance to develop a practical approach to overcoming the barriers to RAASi use and the reinitiation/up-titration of therapy

Target Audience

Cardiologists
Heart Failure Specialists
Nephrologists
Other Allied HCPs

More from this programme

Part 1

RAASi Management in CKD/HF: What We Should Be Doing

3 sessions
Background and Guidelines	Watch now
Case Presentation	Watch now
Panel Discussion and Q&A	Watch now

Part 2

RAASi Management in CKD/HF: What Is Happening in The Real World?

2 sessions
Barriers and Real-world Evidence	Watch now
Panel Discussion and Q&A	Watch now

Part 3

Key Learnings / Summary

1 session
Key Learnings / Summary	Watch now

Faculty Biographies

Aaron Wong

Aaron Wong

Consultant Cardiologist

Dr Aaron Wong is consultant cardiologist and general physician at the Princess of Wales Hospital, Wales, UK and is also an honorary lecturer at the University of Cardiff, UK.

His research interests include heart failure and cardiometabolic disease.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.